Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2026)

Emergent BioSolutions' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 21.74% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was $9.3 million, a 232.14% increase from a year earlier, with the FY2025 full-year figure at $9.8 million, up 32.43% from the prior year.
• Amortization of Deferred Charges eased to $1.8 million in Q1 2026 per EBS's latest filing, from $2.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $8.9 million in Q2 2023 and bottomed at -$6.7 million in Q3 2024.
• The 5-year median for Amortization of Deferred Charges is $2.3 million (2025), against an average of $2.6 million.
• Across the five-year window, Amortization of Deferred Charges jumped 790.0% in 2023 and slumped 217.54% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.0 million in 2022, then surged by 470.0% to $5.7 million in 2023, then tumbled by 61.4% to $2.2 million in 2024, then increased by 18.18% to $2.6 million in 2025, then slumped by 30.77% to $1.8 million in 2026.
• Per Business Quant, the three latest EBS Amortization of Deferred Charges figures stand at $1.8 million (Q1 2026), $2.6 million (Q4 2025), and $2.5 million (Q3 2025).